美股详情

本页面由Tiger Trade Technology Pte. Ltd.提供服务

Baillie Gifford International Alpha ETF

25.23

+0.01060.04%

成交量：8

成交额：201

市值：3.28亿

市盈率：- -

高：25.23

开：25.22

低：25.23

收：25.22

52周最高：25.97

52周最低：23.97

股本：1,301.20万

流通股本：1,301.20万

量比：0.00

换手率：0.00%

股息：- -

股息率：- -

净资产收益率：--

总资产收益率：--

市净率：--

市盈率(LYR):- -

数据加载中...

总览公司新闻资讯公告

诺和诺德首席执行官：我不会排除收购已经上市的产品或资产。

诺和诺德首席财务官：合理预期公司到2030年应能实现中个位数的复合年增长率增长

减肥药巨头诺和诺德本轮调整，裁掉了1.3万个岗位

诺和诺德首席财务官：目标是在2030年之前，将营业利润率维持在与当前大致持平的水平。

美股异动丨诺和诺德盘初跌超7%，上调全年展望至降幅6%，Wegovy药片Q2销售不及预期

美股异动丨诺和诺德盘初跌超7%，上调全年展望至降幅6%，Wegovy药片Q2销售不及预期

诺和诺德ADR股价跌至盘中低点7.4%。

诺和诺德：墨西哥将成为Wegovy口服药的下一个上市市场。

诺和诺德一年内裁员1.3万人

环球市场播报

诺和诺德美国业务负责人表示，目前Wegovy整体业务中50%的销售以及Wegovy口服药在美国90%的销售来自自费渠道。

诺和诺德美国负责人表示，自一月份以来，诺和诺德在肥胖领域的市场份额大约增加了8个百分点。

诺和诺德首席科学官表示：我们认为新一代GLP-1在疗效、便利性、安全性与耐受性方面或具备差异化优势。

诺和诺德再向礼来“宣战”！CagriSema头对头胜过替尔泊肽，减重12.4%

华尔街见闻

诺和诺德：在REDEFINE 9试验中，CagriSema 1.0毫克/1.0毫克组实现体重降幅21.0%，而安慰剂组

诺和诺德的卡格瑞司玛减重效果优异，减重幅度达 12.4%。

诺和诺德：卡格列塞玛在多个支持性终点上的改善效果均优于安慰剂。

诺和诺德的卡格列赛在REIMAGINE 5试验中减重效果优于替尔泊肽。

诺和诺德首席战略官表示，如果合适的机会出现，我们并不排除在肥胖领域进行收购。

诺和诺德首席科学官表示，公司希望同时将口服和皮下注射剂型的Zenagamtide推向市场。

诺和诺德(NVO.US)抛出230亿美元管线蓝图，市场却不买账! 投资者追问“如何逆风翻盘”

{"basename":"/hans","ssrTDKData":{"titleTemplate":"%s - 老虎证券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎证券,老虎证券开户,老虎券商,老虎证券官网,老虎证券app,tigertrade老虎证券,股票,炒股,新加坡股票交易平台,投资,投资理财","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.0a0bd8dc.png","ogUrl":"https://www.etasphere.com/hans/stock/BGIA/news?page=8"},"companyName":"老虎证券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"BGIA","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"BGIA\",,,,,undefined,":{"symbol":"BGIA","market":"US","secType":"STK","nameCN":"Baillie Gifford International Alpha ETF","latestPrice":25.2294,"timestamp":1791921600000,"preClose":25.2188,"halted":0,"volume":8,"delay":0,"changeRate":0.00042032134756596714,"floatShares":13012033,"shares":13012033,"eps":0,"marketStatus":"未开盘","change":0.0106,"latestTime":"10-13 16:00:00 EDT","open":25.2188,"high":25.2294,"low":25.2294,"amount":201,"amplitude":0,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":1,"ttmEps":0,"tradingStatus":0,"nextMarketStatus":{"tag":"盘前交易","tradingStatus":1,"beginTime":1791964800000},"marketStatusCode":0,"adr":0,"exchange":"NASDAQ","adjPreClose":25.2188,"bidAskSpread":0,"volumeRatio":0.002641},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"BGIA\",,,,,undefined,":{"symbol":"BGIA","floatShares":13012033,"roa":"--","roe":"--","lyrEps":0,"volumeRatio":0.002641,"shares":13012033,"dividePrice":0,"high":25.2294,"amplitude":0,"preClose":25.2188,"low":25.2294,"week52Low":23.9707,"pbRate":"--","week52High":25.97,"institutionHeld":0,"latestPrice":25.2294,"eps":0,"divideRate":0,"volume":8,"delay":0,"ttmEps":0,"open":25.2188,"prevYearClose":25.2,"prevWeekClose":25.3417,"prevMonthClose":24.9683,"prevQuarterClose":24.9683,"fiveDayClose":25.4651,"twentyDayClose":24.9961,"sixtyDayClose":24.2745},"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/BGIA\",params:#limit:5,,,undefined,":[],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"BGIA\",market:\"US\",,,undefined,":[],"@#url:\"https://hq.skytigris.cn/fundamental/estimate/recommendation\",params:#symbol:\"BGIA\",market:\"US\",delay:false,,,undefined,":{},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"BGIA\",pageSize:20,pageCount:8,lang_content:\"cn\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2669161801","title":"诺和诺德首席执行官：我不会排除收购已经上市的产品或资产。","url":"https://stock-news.laohu8.com/highlight/detail?id=2669161801","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2669161801?lang=zh_cn&edition=fundamental","pubTime":"2026-09-21 22:27","pubTimestamp":1790000834,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.zhitongcaijing.com/immediately.html?type=usstock","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_zhitongcaijing","symbols":["IPOS","BGIA"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2669169240","title":"诺和诺德首席财务官：合理预期公司到2030年应能实现中个位数的复合年增长率增长","url":"https://stock-news.laohu8.com/highlight/detail?id=2669169240","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2669169240?lang=zh_cn&edition=fundamental","pubTime":"2026-09-21 22:13","pubTimestamp":1789999986,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.zhitongcaijing.com/immediately.html?type=usstock","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_zhitongcaijing","symbols":["BGIA"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2669318161","title":"减肥药巨头诺和诺德本轮调整，裁掉了1.3万个岗位","url":"https://stock-news.laohu8.com/highlight/detail?id=2669318161","media":"第一财经","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2669318161?lang=zh_cn&edition=fundamental","pubTime":"2026-09-21 22:08","pubTimestamp":1789999702,"startTime":"0","endTime":"0","summary":"去年9月份宣布要裁员9000人的诺和诺德，于9月21日在伦敦举办的资本市场日上披露了最终减员情况。诺和诺德方面表示，通过本轮组织调整，公司节约成本超100亿（15.35亿美元）丹麦克朗，帮助公司重新投向商业化与研发；过往调整累计涉及约1.3万个岗位，目前全球全职员工为6.6万人。诺和诺德本轮人员优化背后，核心动因是支撑公司七成以上营收的王牌产品司美格鲁肽，正面临增长承压的挑战。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"stock_eastmoney","url":"http://finance.eastmoney.com/a/202609213880315953.html","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202609213880315953.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["FHLC","IYH","THNR","NVOC","MEDI","NBDS","NVOX","NVOH","FXH","PJP","RSPH","CURE","BGIA","PINK","TRUH","XLVI"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2669169498","title":"诺和诺德首席财务官：目标是在2030年之前，将营业利润率维持在与当前大致持平的水平。","url":"https://stock-news.laohu8.com/highlight/detail?id=2669169498","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2669169498?lang=zh_cn&edition=fundamental","pubTime":"2026-09-21 22:06","pubTimestamp":1789999615,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.zhitongcaijing.com/immediately.html?type=usstock","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_zhitongcaijing","symbols":["BGIA"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2669297169","title":"美股异动丨诺和诺德盘初跌超7%，上调全年展望至降幅6%，Wegovy药片Q2销售不及预期","url":"https://stock-news.laohu8.com/highlight/detail?id=2669297169","media":"格隆汇","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2669297169?lang=zh_cn&edition=fundamental","pubTime":"2026-09-21 22:06","pubTimestamp":1789999569,"startTime":"0","endTime":"0","summary":"诺和诺德(NVO.US)盘初大跌超7%。消息面上，诺和诺德上调全年展望，今年销售额和利润的最大降幅可能为6%，此前预测降幅可能高达12%。Q2 Wegovy药片销售额为32.2亿丹麦克朗，低于预期的32.7亿克朗。Wegovy被认为是现代肥胖症药物中最成功的新品之一，市场对其寄予厚望。\n\n美股频道更多独家策划、专家专栏，免费查阅>>\n\n            责任编辑：山上","market":"fut","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://usstock.jrj.com.cn/2026/09/21220658502008.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"jinrongjie_highlight","symbols":["BGIA"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2669116946","title":"美股异动丨诺和诺德盘初跌超7%，上调全年展望至降幅6%，Wegovy药片Q2销售不及预期","url":"https://stock-news.laohu8.com/highlight/detail?id=2669116946","media":"格隆汇","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2669116946?lang=zh_cn&edition=fundamental","pubTime":"2026-09-21 22:06","pubTimestamp":1789999569,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.gelonghui.com/rss/live/live.xml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_gelonghui","symbols":["BGIA"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2669691601","title":"诺和诺德ADR股价跌至盘中低点7.4%。","url":"https://stock-news.laohu8.com/highlight/detail?id=2669691601","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2669691601?lang=zh_cn&edition=fundamental","pubTime":"2026-09-21 22:03","pubTimestamp":1789999394,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.zhitongcaijing.com/immediately.html?type=usstock","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_zhitongcaijing","symbols":["DINT","APIE","CVY","AADR","ARMH","DIVL","SAPH","BGIA"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2669816520","title":"诺和诺德：墨西哥将成为Wegovy口服药的下一个上市市场。","url":"https://stock-news.laohu8.com/highlight/detail?id=2669816520","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2669816520?lang=zh_cn&edition=fundamental","pubTime":"2026-09-21 20:57","pubTimestamp":1789995431,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.zhitongcaijing.com/immediately.html?type=usstock","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_zhitongcaijing","symbols":["BGIA","IPOS"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2669165759","title":"诺和诺德一年内裁员1.3万人","url":"https://stock-news.laohu8.com/highlight/detail?id=2669165759","media":"环球市场播报","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2669165759?lang=zh_cn&edition=fundamental","pubTime":"2026-09-21 20:52","pubTimestamp":1789995120,"startTime":"0","endTime":"0","summary":"诺和诺德周一表示，过去一年公司裁员 1.3 万人。在面向投资者的演示材料中，诺和诺德称过去一年又有 4000 人离开公司。投资者期待诺和诺德夺回被礼来抢占的市场份额。近几个月诺和诺德多项临床试验遇挫，其中一款旨在降低心梗风险的药物，近期在三期临床试验宣告失败。不过，诺和诺德在减重口服药领域仍领先礼来，其下一代肥胖药物 CagriSema 预计明年上市。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.sina.com.cn/stock/usstock/c/2026-09-21/doc-inisqzxz5966167.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["BGIA"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2669163089","title":"诺和诺德美国业务负责人表示，目前Wegovy整体业务中50%的销售以及Wegovy口服药在美国90%的销售来自自费渠道。","url":"https://stock-news.laohu8.com/highlight/detail?id=2669163089","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2669163089?lang=zh_cn&edition=fundamental","pubTime":"2026-09-21 20:24","pubTimestamp":1789993453,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.zhitongcaijing.com/immediately.html?type=usstock","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_zhitongcaijing","symbols":["BGIA"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2669163293","title":"诺和诺德美国负责人表示，自一月份以来，诺和诺德在肥胖领域的市场份额大约增加了8个百分点。","url":"https://stock-news.laohu8.com/highlight/detail?id=2669163293","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2669163293?lang=zh_cn&edition=fundamental","pubTime":"2026-09-21 20:17","pubTimestamp":1789993070,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.zhitongcaijing.com/immediately.html?type=usstock","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_zhitongcaijing","symbols":["BGIA"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2669716862","title":"诺和诺德首席科学官表示：我们认为新一代GLP-1在疗效、便利性、安全性与耐受性方面或具备差异化优势。","url":"https://stock-news.laohu8.com/highlight/detail?id=2669716862","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2669716862?lang=zh_cn&edition=fundamental","pubTime":"2026-09-21 19:30","pubTimestamp":1789990240,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.zhitongcaijing.com/immediately.html?type=usstock","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_zhitongcaijing","symbols":["BGIA","JDOC"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2669723157","title":"诺和诺德再向礼来“宣战”！CagriSema头对头胜过替尔泊肽，减重12.4%","url":"https://stock-news.laohu8.com/highlight/detail?id=2669723157","media":"华尔街见闻","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2669723157?lang=zh_cn&edition=fundamental","pubTime":"2026-09-21 19:02","pubTimestamp":1789988564,"startTime":"0","endTime":"0","summary":"诺和诺德公布旗下减重药CagriSema最新临床数据：在与礼来替尔泊肽的直接比较中，CagriSema平均减重12.4%，高于替尔泊肽的9.1%；另一项试验中减重达21%。目前该药已提交FDA审批，预计今年第四季度迎来结果。","market":"nz","thumbnail":"https://static.tigerbbs.com/fb4be1ff4aaa40ac88564f80f173158e","type":0,"news_type":0,"thumbnails":["https://static.tigerbbs.com/fb4be1ff4aaa40ac88564f80f173158e"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://wallstreetcn.com/articles/3782221","is_publish_highlight":true,"source_rank":0,"column":"","sentiment":"0","news_top_title":"诺和诺德再向礼来“宣战”！CagriSema头对头胜过替尔泊肽，减重12.4%","news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["NVOH","BGIA","NVO","NVOC","NVOX"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2669157581","title":"诺和诺德 ：在REDEFINE 9试验中，CagriSema 1.0毫克/1.0毫克组实现体重降幅21.0%，而安慰剂组","url":"https://stock-news.laohu8.com/highlight/detail?id=2669157581","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2669157581?lang=zh_cn&edition=fundamental","pubTime":"2026-09-21 18:27","pubTimestamp":1789986423,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.zhitongcaijing.com/immediately.html?type=usstock","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_zhitongcaijing","symbols":["BGIA"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2669575841","title":"诺和诺德的卡格瑞司玛减重效果优异，减重幅度达 12.4%。","url":"https://stock-news.laohu8.com/highlight/detail?id=2669575841","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2669575841?lang=zh_cn&edition=fundamental","pubTime":"2026-09-21 18:25","pubTimestamp":1789986342,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.zhitongcaijing.com/immediately.html?type=usstock","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_zhitongcaijing","symbols":["BGIA"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2669157322","title":"诺和诺德：卡格列塞玛在多个支持性终点上的改善效果均优于安慰剂。","url":"https://stock-news.laohu8.com/highlight/detail?id=2669157322","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2669157322?lang=zh_cn&edition=fundamental","pubTime":"2026-09-21 18:25","pubTimestamp":1789986321,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.zhitongcaijing.com/immediately.html?type=usstock","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_zhitongcaijing","symbols":["BGIA"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2669715737","title":"诺和诺德的卡格列赛在REIMAGINE 5试验中减重效果优于替尔泊肽。","url":"https://stock-news.laohu8.com/highlight/detail?id=2669715737","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2669715737?lang=zh_cn&edition=fundamental","pubTime":"2026-09-21 18:24","pubTimestamp":1789986281,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.zhitongcaijing.com/immediately.html?type=usstock","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_zhitongcaijing","symbols":["BGIA"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2669522321","title":"诺和诺德首席战略官表示，如果合适的机会出现，我们并不排除在肥胖领域进行收购。","url":"https://stock-news.laohu8.com/highlight/detail?id=2669522321","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2669522321?lang=zh_cn&edition=fundamental","pubTime":"2026-09-21 18:12","pubTimestamp":1789985535,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.zhitongcaijing.com/immediately.html?type=usstock","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_zhitongcaijing","symbols":["BGIA"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2669152912","title":"诺和诺德首席科学官表示，公司希望同时将口服和皮下注射剂型的Zenagamtide推向市场。","url":"https://stock-news.laohu8.com/highlight/detail?id=2669152912","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2669152912?lang=zh_cn&edition=fundamental","pubTime":"2026-09-21 18:03","pubTimestamp":1789985039,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.zhitongcaijing.com/immediately.html?type=usstock","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_zhitongcaijing","symbols":["BGIA"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2669151761","title":"诺和诺德(NVO.US)抛出230亿美元管线蓝图，市场却不买账! 投资者追问“如何逆风翻盘”","url":"https://stock-news.laohu8.com/highlight/detail?id=2669151761","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2669151761?lang=zh_cn&edition=fundamental","pubTime":"2026-09-21 17:24","pubTimestamp":1789982648,"startTime":"0","endTime":"0","summary":"诺和诺德美股ADR在周一美股盘前也大幅走弱，一度大跌超过7%。诺和诺德最新的230亿美元目标销售额似乎不及市场预期。尽管诺和诺德率先推出了新一代强效药物，使肥胖症变得更易治疗，但它仍落后于礼来。诺和诺德此前表示，今年整体利润以及营收最多可能下降6%。诺和诺德此次提出的新药蓝图，体现了其通过产品迭代争取下一轮增长的意图。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1498757.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BGIA"],"isVideo":false,"video":null,"gpt_icon":0}],"pageSize":20,"totalPage":10,"pageCount":8,"totalSize":199,"code":"91000000","status":"200"}]}}